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Abstract
Bronchiolitis obliterans syndrome (BOS) is the major obstacle to long-term survival after lung transplantation, yet markers
for early detection and intervention are currently lacking. Given the role of regulatory T cells (Treg) in modulation of
immunity, we hypothesized that frequencies of Treg in bronchoalveolar lavage fluid (BALF) after lung transplantation would
predict subsequent development of BOS. Seventy BALF specimens obtained from 47 lung transplant recipients were
analyzed for Treg lymphocyte subsets by flow cytometry, in parallel with ELISA measurements of chemokines. Allograft
biopsy tissue was stained for chemokines of interest. Treg were essentially all CD45RA2, and total Treg frequency did not
correlate to BOS outcome. The majority of Treg were CCR4+ and CD1032 and neither of these subsets correlated to risk for
BOS. In contrast, higher percentages of CCR7+ Treg correlated to reduced risk of BOS. Additionally, the CCR7 ligand CCL21
correlated with CCR7+ Treg frequency and inversely with BOS. Higher frequencies of CCR7+ CD3+CD4+CD25hiFoxp3+C-
D45RA2 lymphocytes in lung allografts is associated with protection against subsequent development of BOS, suggesting
that this subset of putative Treg may down-modulate alloimmunity. CCL21 may be pivotal for the recruitment of this
distinct subset to the lung allograft and thereby decrease the risk for chronic rejection.
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Introduction
Lung transplantation is a therapeutic option for end-stage lung
disorders, but is complicated by allograft rejection with an incidence
and severity that is among the highest of solid organ transplants [1].
Long-term survival is largely dependent upon recipients remaining
free of bronchiolitis obliterans syndrome (BOS). BOS is a chronic
alloimmune mediated, fibro-obliterative syndrome characterized by
progressive airflow obstruction and graft dysfunction [2–5]. BOS
affects over 60% of lung transplant recipients within five years after
transplantation [1,6,7] and imparts a 3-year mortality of. 50% [1].
Over the last 20 years nearly 10,000 lung transplants have been
performed in the USA, suggesting that over 6,000 individuals have
developed and 3,000 died from BOS; a tremendous human and
financial burden [8]. Despite BOS being a major obstacle to long-
term survival post-lung transplantation, there is presently no
effective means of early detection, prevention, or treatment [9].
The regulatory T lymphocyte (Treg, CD3+CD4+CD25hi-
Foxp3+) is recognized as a cell integral to protection against
autoimmunity and allograft rejection via the down-regulation of
cellular immunity [10–17]. Treg are believed to suppress the
activity of alloreactive, effector CD4+ and CD8+ T cells, and
thereby contribute to allograft survival [18–21]. To our knowl-
edge, no studies have examined the frequency of bronchoalveolar
lavage fluid (BALF) Treg subsets or the chemokines responsible for
their recruitment and accumulation in the lung allograft.
We recently found no difference in BALF Treg (CD4+CD25hi-
Foxp3+) frequencies and ratios to effector T cells (CD8+CD38+) in
lung transplant recipients with or without rejection [22], although
some recipients with increased Treg during rejection did not go on
to develop BOS (unpublished data). We therefore hypothesized
that allograft Treg may be protective against BOS. Herein we
describe our characterization of Treg subsets and chemokine
protein expression in BALF from a larger cohort of lung transplant
recipients with known BOS outcomes.
Materials and Methods
Study Design and Patient Population
Forty-seven participants underwent routine screening bron-
choscopy with transbronchial biopsy and were recruited non-
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consecutively between December 2006 and December 2008 from
patients in the UCLA Medical Center Heart and Lung
Transplantation Program, who had undergone single, bilateral
or combined heart and lung transplantation. For this cross-
sectional analysis seventy BALF were randomly collected for Treg
and Treg subset analysis at times post-transplantation that were
not pre-specified. In April of 2009 the BOS status of recipients for
whom BALF was analyzed by FACS was determined as described
below; there was no pre-specified follow-up time.
Ethics Statement
Each participant provided written, informed consent under a
University of California, Los Angeles Institutional Review Board-
approved protocol that specifically approved of this study.
BALF Processing
Thirty to fifty mL of bronchoalveolar lavage fluid was
immediately placed on ice after collection and processed within
six hours. BALF was filtered through sterile 464 inch cotton gauze
into sterile 50 mL conical centrifuge tubes and spun down, and the
eluate was saved for protein analysis. The cell pellet was washed
with 30 mL of sterile phosphate buffered saline solution (PBS) and
then viably cryopreserved in fetal calf serum (FCS) with 10%
DMSO (Sigma) for later batch analysis. Control experiments were
consistent with our previous published observations and showed
that fresh versus frozen cells yielded similar results [22]. The BALF
fraction taken for protein analysis was re-centrifuged for 10
minutes at 500xg. The cell-free solution was aliquoted and frozen
immediately at 270uC until thawed for chemokine ELISA.
Cell Staining for Flow Cytometry
Frozen BALF cells were thawed in R10 (RPMI, 10% heat-
inactivated FCS, HEPES, triple antibiotic) then resuspended in
PBS and allowed to incubate for 20 minutes at 37uC with LIVE/
DEAD Blue (Invitrogen). The reaction was quenched with the
addition of R10. BALF cells were resuspended in PBS with 4%
Figure 1. Representative gating strategy for identification of CD3+CD4+CD25hiFoxp3+ lymphocytes and subsets. Gated cells (selected
cells) are purple, while non-gated cells (discarded cells) are blue or black. The gating involves sequential boolean filters and the sequence of filters is
demonstrated here moving left to right and then top to bottom. Purple cell populations are selected in each scatterplot and this population is then
used as the parent population in the subsequent scatterplot. (top row) First, singlets are identified in a forward scatter-area vs. forward scatter-height
plot and gated on prior to logicle transformation of the data. Live/CD4+ cells are then identified in a CD4 vs. UV-Blue plot. CD3+ cells are then
identified in a CD4 vs. CD3 plot. (bottom row) Lymphocytes within this population are identified in a side scatter-area vs. forward scatter-area plot.
Treg are identified in a Foxp3 vs. CD25 plot. Determination of gates for CD25, CD45RA, Foxp3 and CCR7 utilized fluorescence minus-one (FMO) tubes.
doi:10.1371/journal.pone.0011354.g001
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FCS and 0.1% sodium azide, and incubated with the following
monocolonal antibodies for 30 minutes at 4uC: anti-CD3-
AmCyan (BD Biosciences), anti-CD4-APC-H7 (BD Pharmingen),
anti-CD25-AlexaFluor647 (Biolegend), anti-CD45RA-Cy5.5-
PerCP (eBioscience), anti-CCR7-Cy7PE (BD Pharmingen), anti-
CCR4-phycoerythrin (PE) (R&D Systems) and anti-CD103-
fluorescein isothiocyanate (FITC) (eBioscience). Cells were then
stained with intracellular anti-Foxp3-Pacific Blue (clone PCH101)
(eBioscience) as per the manufacturer’s recommendations, fol-
lowed by washing and fixation in 1% paraformaldehyde.
Acquisition was performed using a LSR II (BD Biosciences)
cytometer with the following configuration: 1) Blue laser (488 nm)
with the following filters 785LP (780/60), 685LP (695/40), 600LP
(610/20), 550LP (575/26), 505LP (525/50); 2) Red laser (640 nm)
with 755LP (780/60), 685LP (710/50), 660/20; 3) Violet laser
(405 nm) with 635LP (660/40), 595LP (605/40), 505LP (525/50),
450/50; and 4) UV light (355 nm) with 505LP (525/50) and 450/
50. Compensation was performed using singly-stained tubes of
each conjugated fluorochrome and BD CompBeads (BD Biosci-
ences). Sphero Rainbow Fluorescent Particles (3.0–3.4micron)
(Spherotech) were used for laser and detector calibration prior to
each flow run.
Flow Cytometry Analysis
The regulatory T lymphocyte (Treg defined as CD3+CD4+CD25hi-
Foxp3+ herein) and subsets expressing CCR4, CCR7, CD103 (the
integrin alphaEbeta7) and/or CD45RA were determined. A repre-
sentative gating strategy is shown in Figure 1. Singlets were identified
in a forward scatter-area (FSC-A) vs. forward scatter-height (FSC-H)
plot and gated on prior to logicle transformation of the data [23].
Live/CD4+ cells were identified in a CD4 vs. UV-Blue plot. CD4+/
CD3+ cells were then identified in a CD4 vs. CD3 plot. CD4+
lymphocytes within this population were identified in a side scatter-
area (SSC-A) vs. FSC-A plot. Treg were identified in a Foxp3 vs.
CD25 plot. Determination of gates for CD25, CD45RA, Foxp3,
CCR7, CCR4 and CD103 was done by corresponding fluorescence
Figure 2. Flow chart description of the number of samples and outcomes from each group. Forty-seven lung transplant recipients were in
the study. Thirteen went on to develop BOS. Seventy BALF samples were collected and ten had insufficient cells to allow detection of Treg, thus 60
samples were used for total Treg analysis. Of the 60 samples, 27 were dropped from analysis for the Treg subsets due to inadequate number of Treg
as explained in the Methods.
doi:10.1371/journal.pone.0011354.g002
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minus-one (FMO) control tubes. In addition, an internal control of
Live CD3+CD42CD25hiFoxp3+ lymphocytes was used to determine
background staining for Live CD3+CD4+CD25hiFoxp3+ lymphocytes
(Treg). The lowest limit of detection above this background was pre-
specified as 2*SD of the number of positive events within the Treg gate
in this internal control population. These methods were required to
statistically account for the rare event analysis of putative Treg subsets.
Ten BALF samples of 70 were excluded from the analysis of total Treg
due to poor sample quality as assessed by flow cytometry, leaving 60
samples for total Treg analysis (Figure 2). For analysis of Treg subsets,
a further 27 samples were excluded due to insufficient Treg as per our
pre-specified detection limit, leaving 33 samples for Treg subset
analysis. There was only one BALF sample per recipient in the Treg
subset analyses.
ELISA Assays
Human CCL19, CCL21, CCL17 and CCL22 protein levels
from the unconcentrated BALF samples were quantified using
DuoSet ELISA development kits (R&D Systems, Minneapolis,
MN). We attempted to recover BALF protein from samples after
we had run FACS. Unfortunately, 23 samples went through a
freeze-thaw which causes degradation of chemokine proteins.
Thus nine samples from our Treg subset analysis were available
for BALF chemokine protein analysis.
Immunohistochemical Staining
For immunohistochemical staining slides were ‘‘deparafined’’ by
incubation at 60uC for 30 minutes followed by immersion in
xylene then in decreasing concentrations of ethanol (100, 95, 70%)
as previously described [24,25]. The slides were placed in a
pressure cooker with citrate buffer for 30 minutes for antigen
retrieval, prior to rinsing with de-ionized water. Slides are then
placed in the modified endogenous blocking solution (PBS +3%
H202) for 10 minutes. Antibody labeling was achieved by first
flooding the slide with appropriate blocking solution (3% normal
rabbit serum) and incubating for 30 minutes. The primary
antibody was applied (anti-human CCL21 antibody (R&D
Systems) or the appropriate isotype control IgG) and incubated
for 30 minutes at room temperature, overnight at 4uC, then 30
minutes at room temperature, followed by a series of washes with
PBS + tween. The slides were then flooded with Vectastain Elite
ABC reagent (Vector Laboratory, Inc.) and allowed to incubate 40
minutes. After a PBS + tween rinse, the horseradish peroxidase-
bound avidin-biotin was applied and DAB solution was added
until development had reached desired level, then the reaction was
quenched with water. The counterstaining was accomplished by
dipping the slide in hematoxylin (Biomeda), rinsing then dipping in
10% ammonia and the rinsing in escalating concentrations of
ethanol culminating in a xylene rinse.
Acute Rejection, BOS and Immunosuppression
Acute rejection (AR) and BOS, $ Stage I, was determined
according to standard criteria by investigators blinded to the
experimental study results [26]. Patients were placed on pre- and
post-transplantation immunosuppression of tacrolimus (8–20 mg/
mL 12 hour trough), mycophenolate mofetil (MMF) 1000 mg
orally BID (dose adjusted for toxicity), prednisone (intra-operative
methylprednisolone 7 mg/kg times one, then 125 mg every
12 hours for three doses, then 0.5 mg/kg daily for one week
post-transplantation with a 5 mg per week taper to a baseline of 5–
15 mg daily) and prophylactic antibiotics (trimethoprim-sulfa-
methoxazole 160 mg BID Mondays and Thursdays and valganci-
clovir 450–900 mg daily). Unless contraindicated, all patients
received induction therapy with either rabbit anti-thymocyte-
globulin (1.5 mg/kg on post-operative days 0, 1 and 2) or, if over
the age of 65 or at increased risk of malignancy or infection as
perceived by the transplant physician, basiliximab (20 mg on post-
operative days 0 and 4). Rapamycin was not initiated prior to the
diagnosis of BOS in any study patient. Asymptomatic AR grade
A1 was treated with recycling of oral prednisone at the discretion
of the attending pulmonologist. Clinically significant/symptomatic
AR .= grade A1 was treated with pulse methylprednisolone,
thymoglobulin, basiliximab, alemtuzumab, and/or IVIg at the
physician’s discretion.
Statistical Analysis
Data collection and cell quantification was performed in a
blinded fashion. The Chi-square test of association for categorical
variables, the nonparametric Wilcoxon rank-sum tests for
continuous variables over time and Kendall’s Rank Correlation
test to measure correlations between variables and ordinal
outcomes have been applied. The Cox proportional hazards
model was used to assess differences in time to BOS between
variables of interest with interval censoring. Descriptive statistics
are presented as medians [25th, 75th quantiles]. There was no
adjustment for multiplicity in this exploratory analysis. The ROC
curve was drawn to test the power of the predicted values from the
logistic regression model, to discriminate between positive and
Table 1. Descriptive statistics by BOS outcome for Treg
subset analysis (CCR7+ and CCR4+ subsets).
No BOS
N=23 BOS N=10 Test Statistic
Lymphocytic Bronchitis 13% (2) 60% (6) X2 = 6, p = 0.011
Rejection 22% (5) 30% (3) X2 = 0.26, p = 0.611
Infection 4% (1) 10% (1) X2 = 0.39, p = 0.531
Age 58[49, 61] 60[54, 62] F1,31 = 0.17, p = 0.67
2
Male Sex 43% (10) 50% (5) X2 = 0.12, p = 0.731
Pre-Tx Diagnosis: X2 = 13.6, p = 0.061
Cystic Fibrosis 0% (9) 10% (1)
COPD 39% (9) 0% (0)
IPF 39% (9) 60% (6)
LAM 0% (0) 20% (2)
Bronchiectasis 4% (1) 0% (0)
Pulmonary HTN 4% (1) 0% (0)
Sarcoid 9% (2) 0% (0)
Scleroderma 4% (1) 10% (1)
Acute Rejection Grade: X2 = 2.29, p = 0.521
0 67% (10) 70% (7)
1 27% (4) 20% (2)
2 7% (1) 0% (0)
3 0% (0) 10% (1)
Sample Day Post-Tx 61[1, 167] 97[48, 293] F1,31 = 02.25, p = 0.14
2
N is the number of non-missing values.
Numbers after percents are frequencies.
a[b, c] represents the median a, lower quartile b and the upper quartile c for
continuous variables.
Tests used:
1Pearson test;
2Wilcoxon test.
doi:10.1371/journal.pone.0011354.t001
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negative cases. All tests were two sided and performed in R
[27–29] and BioConductor [30–32].
Results
Lung Transplant Patient Population and BOS Outcomes
Seventy BALF samples were collected prospectively on 47 lung
transplant recipients who underwent routine screening after
transplantation (Figure 2). These samples were collected at a
median of 91.5 [7, 184] days post-transplantation. Concurrent
transbronchial biopsies were available for the 70 BALF collections
with 14 episodes of AR, including nine grade 1, three grade 2, two
grade 3, and 19 with lymphocytic bronchitis (many samples had
concurrent lymphocytic bronchitis and rejection).
Recipients were followed for a median of 633 [291,732] days post-
transplantation to determine BOS outcome. Thirteen recipients
(28%) developed BOS at 254 [231, 457] days. The ages of the
subjects with and without development of BOS were similar (59
[54, 62] vs. 59 [54, 64], p=0.98). The timing of sample collection
after transplantation was also similar between those with and without
development of BOS (113 [40, 270] vs. 63 [7, 183] days, p=0.10).
Four samples had concurrent infections with two bacterial pneumo-
nias in each group. Further descriptors for all recipients with samples
included in the Treg subset (33) analysis is given in Table 1.
Total CD3+CD4+CD25hiFoxp3+ Lymphocyte (Treg)
Population Did Not Predict Subsequent BOS
The frequencies of CD3+CD4+CD25hiFoxp3+ lymphocytes (Treg)
in BALF from routine post-transplant bronchoscopies were assessed
(Figure 2). Consistent with the reported memory phenotype of Treg,
essentially all of these cells were CD45RA2 (100% [99.4, 100]).
Comparing samples from subjects who subsequently developed BOS
to those who did not during follow-up, there was no significant
difference in the frequency of this total Treg population (4.5% [1.8,
6.5] vs. 4.2% [2.5, 7.3], p=0.92) (Figure 3). This relationship was
further evaluated with the Cox Proportional Hazards (Cox) model to
account for the time from sample collection to the development of
BOS. In the Cox model we found no association in either direction
(HR= .0, p=0.96) (Figure 4). Limiting analysis to those samples taken
during documented acute rejection (14 subjects) also demonstrated no
difference in Treg frequencies between recipients with or without
development of BOS (p=0.76). There was no correlation with total
Treg and time of sample post-transplantation (tau=20.002, p=0.98).
Subpopulations of Treg with CCR4 or CD103 Did Not
Correlate With Development of BOS
We next considered subpopulations of Treg that might be better
indicators of immunoregulatory activity, with the hypothesis that
recruitment and retention within the allograft is crucial for effective
Treg activity against rejection. Subsets of Treg defined by CCR4 (a
pivotal chemokine receptor shown to recruit Treg to inflammatory
sites and allografts) [33,34] or CD103 (an alphaEbeta7 integrin
involved in trafficking of T cells to inflammatory sites) [35,36] were
assessed for prediction of BOS. The majority of Treg expressed
CCR4 (Figure 5), but Treg expression of CCR4 did not demonstrate
a significant difference between recipients with and without
development of BOS during study follow-up (77.5% [70.9,85.2] vs.
86.5% [79.6,95.4], p=0.12) (Figure 3). We further found no
association of CCR4 expression on Treg and the subsequent
development of BOS in the Cox model (HR=0.94, p=0.08)
(Figure 4). There was no trend of CCR4 expression with time of
sample after transplantation (tau=20.04, p=0.73). Virtually none
of the CD3+CD4+CD25hiFoxp3+CD45RA2 lymphocytes expressed
CD103 (0.0% [0.0, 0.0]). Thus, neither CCR4 nor CD103 expression
was reflective of Treg subsets that potentially protected against BOS.
CCR7 Expression on Treg is Associated With Protection
From BOS
As studies have noted that CCR7 can be expressed by Treg and
may be critical for Treg trafficking between lymphatic and
allograft tissue [34], we determined if CCR7 was expressed on our
Figure 3. Boxplots of T regulatory lymphocytes and BOS outcomes. (left) A boxplot of all 60 evaluable samples for total Treg. This plot
demonstrates that there are no differences in total Treg frequencies between those recipients who eventually develop BOS and those that do not
(p = 0.92). (middle) A boxplot of all 33 evaluable samples for Treg subsets. This plot demonstrates that there are no differences in CCR4+ Treg
frequencies between those recipients who eventually develop BOS and those that do not (p = 0.12). (right) A boxplot of all 33 evaluable samples for
Treg subsets. The CCR7+ subset is associated with protection against BOS (p = 0.04).
doi:10.1371/journal.pone.0011354.g003
CCR7 Treg Prevent BOS
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BALF Treg. Overall, the expression of CCR7 on Treg was
variable between subjects, with a median of 18.8% [9.1, 47.0]
(Figure 5). Notably, the median frequency of the CCR7+ Treg
subset was significantly higher in those that did not develop BOS
than in those that did subsequently develop BOS (29.1% [14.3,
50.7] vs. 9.8% [7.8, 11.1] p = 0.04) (Figure 3). Importantly, this
finding was also supported by the Cox model which accounted for
sample collection time in relation to the development of BOS
(HR=0.94, p= 0.04) (Figure 4). The expression of CCR4 by
CCR7+ versus CCR72 Treg was similar (89.2% [69.1, 100] vs.
84.2% [72.9, 95.7], p . 0.10), indicating that CCR4 did not play
a major role in distinguishing trafficking of these subsets to the
lung allograft. There was not a significant trend of CCR7
expression with time of sample collection post-transplantation
(tau =20.02, p= 0.88). These results suggest that CCR7 is a
marker of a key subset of Treg that may protect against BOS.
CCL21 Protein Levels in BALF Correlate with CCR7+ Treg
Frequencies
Having observed that higher frequencies of CCR7+ Treg in lung
allograft BALF are associated with reduced incidence of BOS, we
sought to identify potential chemokines that drive recruitment and
retention of these cells in the allograft. The two known ligands for
CCR7, CCL21 (6ckine) and CCL19 (MIP-3beta), were assessed by
ELISA. BALF CCL21 protein levels correlated with frequencies of
CCR7+ Treg (tau=0.34 and p=0.03), while CCL19 did not
(tau=20.11, p=0.47). Given the putative importance of CCR4 for
Treg recruitment, we also assessed the CCR4 ligands CCL17 (TARC)
and CCL22 (MDC). There was no correlation to CCR4+ or CCR7+
subsets nor total Treg frequencies. We further assessed for a correlation
between CCL21 protein levels and BOS outcome and found an
inverse association (tau=20.64 and p=0.04) (see Figure 4). These
results underscore the likely importance of Treg recruitment to the lung
allograft via chemotaxis mediated by the interactions of CCL21 and
CCR7.
Our finding of an association between CCL21 and CCR7+
Treg in BALF led us to investigate the cellular sources of CCL21
in healthy lung allografts. Multiple biopsies (n = 5) from healthy
lung allografts without infection or rejection demonstrated that
CCL21 protein is predominately expressed from bronchiolar
epithelial cells and alveolar macrophages (Figure 6).
Discussion
In this study we describe a unique subpopulation of
CD3+CD4+CD25hiFoxp3+CD45RA2 (Treg) that express CCR7
Figure 4. Plots of the log Cox Relative Hazard ratio for BOS against percent T regulatory lymphocyte subsets. The log of the Cox
Relative Hazard (y-axis) decreases, i.e., less likely to develop BOS, as the percent of Treg, Treg subset or CCL21 protein level (x-axis) increases. The
steeper the curve, as indicated by the blue line, the more protective the association with each Treg subset. The most significant effect is seen with the
CCR7+ Treg subset. Confidence intervals are given by the gray bands. (top left) A plot for total BALF Treg, which demonstrates a non-significant
protective effect. (top right) A plot of percent CCR4+ Treg, which demonstrates no significant protective effect. (bottom left) A plot of percent CCR7+
Treg, which demonstrates a significant protective effect. (botom right) A plot of BALF CCL21 protein level (pg) as determined by ELISA, which
demonstrates a significant protective effect.
doi:10.1371/journal.pone.0011354.g004
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and are associated with protection against the future development
of BOS after lung transplantation. This finding offers a potential
cellular biomarker that could be useful in early prediction of BOS
and provides potential insight into the mechanism of chronic
rejection (Figure 7). Such a biomarker would be a means with
which to limit over-immunosuppression and its associated morbid
risks of infections and cancer.
Our findings suggest that CCR7+ Treg are important for
protection against BOS. This is in agreement with a recent murine
model of islet cell transplantation, wherein maximum suppression
of allograft rejection required the expression of CCR7 on Treg
[34]. Most of our Treg, including the CCR7+ Treg, are CCR4+,
consistent with murine transplantation models that demonstrate
CCR4 expression on Treg in the allograft [33,34]. However, we
find no differences in terms of BOS outcome with the CCR4+
subpopulation. In fact, neither of the CCR4 ligands correlate with
Treg or subpopulation frequencies, suggesting that CCR4 may not
be critical for the maintenance of important Treg subsets within
the allograft. We do demonstrate that the CCR7 ligand CCL21 is
expressed by lung allograft mononuclear and bronchial epithelial
cells and levels in BALF correlate with frequencies of the CCR7+
Treg subset. Additionally, BALF CCL21 appeared protective
against the development of BOS. This data suggests that the
interaction between CCL21 and CCR7+ Treg is a pivotal biologic
axis for Treg recruitment to the lung allograft and for allowance of
protection against BOS.
CD103 is the alphaEbeta7 integrin which binds e-cadherin and
is reportedly present on intraepithelial lymphocytes [35,36].
Previous investigators had noted low overall expression of
CD103 by human, peripheral CD4+CD25+ regulatory lympho-
cytes [37–40] consistent with our findings herein, suggesting that
CD103 may be an important marker for murine Treg but not for
human Treg [41–44].
It should be mentioned that our study has several caveats. This
is not a longitudinal study and BALF samples were not collected at
a uniform time post-transplantation, which may have introduced
unknown biases. While we are able to identify Treg within the
BALF of .87% of the samples, most samples had fewer than 20
Treg (hundreds of lymphocytes), which led to a significant decline
in evaluable samples from 70 to 60 for total Treg evaluation and
from 60 to 33 for Treg subset evaluations (Figure 2). This was
based on our methodology of using internal controls to set a
minimum number of Treg in which subsets could be confidently
assessed. All samples were collected prospectively and longitudi-
nally, but only a few of the 47 subjects have more than one sample
in this cohort preventing identification of within patient trends
Figure 5. Density plots of chemokine receptor expression by Treg. Representative density plots of CCR4 and CCR7 expression by BALF Treg.
The parent populations for determination of chemokine receptor positivity were singlet, live, CD3+CD4+CD25hiFoxp3+ lymphocytes as shown in
Figure 1. (left) Demonstrates the generally high level of CCR4 expression by Treg. The CCR4 gate was determined such that ,0.1% of the cells were
positive in the CCR4 FMO tube (see text for detail). (right) Demonstrates the variability of CCR7 expression by Treg. The CCR7 gate was determined
such that ,0.3% of the cells were positive in the CCR7 FMO tube.
doi:10.1371/journal.pone.0011354.g005
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over time. Importantly, we did not find any trend in Treg or Treg
subset frequencies based on the time of sample collection post-
transplantation. Due to the small numbers of Treg recovered from
the samples we are not able to sort and perform functional assays
to measure suppressive capacity of these CD3+CD4+CD25hi-
Foxp3+CD45RA–CCR7+ cells. This is an inherent weakness in the
study of human BALF samples, which we hope to overcome in
future studies. Furthermore, by the time we analyzed our BALF
Figure 6. Histopathology demonstrating CCL21 production in healthy lung allograft. Representative immunohistochemistry for (a)
control antibody and (b) CCR7 ligand CCL21 on healthy lung allograft biopsy tissue. CCL21 protein expression is found in bronchial epithelial cells
(red arrows) and alveolar macrophages (green arrows). Panels were photographed at 2006 and 4006magnification.
doi:10.1371/journal.pone.0011354.g006
Figure 7. ROC curve for CCR7+ Treg and BOS. The ROC curve is based upon a logistic regression model for CCR7+ Treg predicting BOS outcome,
which excludes samples collected after the diagnosis of BOS. The p-value for the global null hypothesis is 0.04 and the area under the curve (AUC) is
0.75; the model has good predictive value.
doi:10.1371/journal.pone.0011354.g007
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chemokine protein levels all but nine samples had undergone a
freeze thaw process. Thus our analysis for correlation between
BALF protein levels and Treg subsets and BOS should be
interpreted with caution.
To our knowledge, this study is the first to utilize multiparam-
eter flow cytometric analysis of BALF lymphocytes in lung
transplant recipients. Multiparameter FACS is necessary to
exclude non-Treg by using live-dead discrimination dye and
FMO tubes. An internal control is also used to define the
appropriate detection limit in the rare subset event analysis. While
it remains possible that the cells we have captured within the
BALF are distinct from the parenchymal lung cells, prior
publications have noted that such cells are nearly identical both
functionally and phenotypically [45].
The importance of an accurate marker to identify lung
transplant recipients not at risk for BOS cannot be over-
emphasized. Rejection is pervasive post-lung transplantation and
even one episode of A1 has been suggested to increase the
subsequent risk of BOS [46–48], as have primary graft dysfunction
and HLA mismatch [46,49–51]. Augmentation of immunosup-
pression is the usual response to rejection, but it increases the risk
of infection, which may increase long-term risk for BOS [46,52].
Yet to be described are protective factors within the lung allograft
that could help to direct potentially harmful adjunctive immuno-
suppressive therapy away from lung transplant recipients with
reduced risk of BOS.
In conclusion, we describe a novel CCR7+ Treg subpopulation
that may be recruited to the lung allograft by CCL21 and which
correlates with the delayed onset of or protection against
development of BOS. While preliminary, these data suggest that
a CCR7+ subset of Treg is involved in the prevention of chronic
graft dysfunction after lung transplantation. Further studies are
underway to validate this finding in a larger, longitudinal cohort of
patients and to assess the functionality of these cells.
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